Viw Magazine

Men's Weekly

.

Zuellig Pharma and Substipharm Biologics partner to expand access to IMOJEV® vaccine for Japanese encephalitis across Asia

  • Written by Viw Magazine

New commercialisation agreement builds on existing partnership with Zuellig Pharma

SINGAPORE - Media OutReach Newswire - 16 January 2024 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced its commercialisation partnership with pharmaceutical company Substipharm Biologics, to expand access of the IMOJEV® Japanese encephalitis vaccine across nine markets in Asia, including Brunei, Cambodia, Hong Kong, Malaysia, Myanmar, Philippines, Singapore, Taiwan and Vietnam.

Read more

LifeStyle

How Fat Freezing Melbourne Treatments Help Reduce Stubborn Body Fat

Achieving a well-balanced body shape often requires regular exercise and healthy eating habits. Ho...

Why an NDIS Provider Plays a Vital Role in Supporting People With Disabilities

Access to the right support services can significantly improve the quality of life for people livi...

Why Hurstville Tutoring Supports Strong Academic Growth And Confidence

Students in academically competitive areas often face increasing pressure to perform well across m...

Is a Pop Top Caravan Suitable for a Family of Four?

For families planning road trips across Australia, choosing the right caravan layout can shape the...